Evolutionary Genomics Inc (FNAM) Return on Equity ROE from the fourth quarter 2022 to fourth quarter 2021 and annually, average high and low, overall ranking from Dec 31 2022 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Evolutionary Genomics Inc   (FNAM)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Evolutionary Genomics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Evolutionary Genomics Inc in the fourth quarter 2022?
Due to the lack of equity, it was not possible to calculate Evolutionary Genomics Inc 's return on equity (ROE) in its fourth quarter 2022

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -2 -2 -3 -3 -3
Return On Equity (TTM) - - - - -
FNAM's Total Ranking # # # # #
Equity (TTM) in Millions -6 -5 -5 -4 -4
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to FNAM Management Effectiveness >> FNAM's 5 Years Annual ROE >> Compare FNAM ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





FNAM Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions -6 -4 -2 0 0
Y / Y Equity Change - - - - -71.25 %
Net Income in Millions -2 -3 -2 -1 -1
Y / Y Net Income Change - - - - -
Return On Equity - - - - -272.21 %

Back to FNAM Management Effectiveness >> FNAM's 5 Years Annual ROE >> Compare FNAM ROE to its Competitors




More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
FNAM's' Return on Equity at Yahoo Finance
FNAM's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for FNAM's Competitors
Subscribers only: Roe for Evolutionary Genomics Inc 's Suppliers
Subscribers only: Return On Equity for FNAM's Customers




Companies with similar Return On Equity at Dec 31 2022, within Healthcare Sector ROE
Halozyme Therapeutics Inc   98.57 %
Biomx Inc  94.11 %
Davita Inc   92.73 %
Vaso Corporation  80.20 %
Opus Genetics Inc   79.52 %
Abbvie Inc   73.67 %
Assertio Holdings inc   72.98 %
Kiniksa Pharmaceuticals International Plc  66.68 %
Novo Nordisk A  65.46 %
Tff Pharmaceuticals Inc  65.46 %
Dynavax Technologies Corporation  65.38 %
Dariohealth Corp   64.99 %
Avid Bioservices Inc   64.65 %
Eli Lilly And Company  63.95 %
Aptevo Therapeutics Inc   63.08 %
Maravai Lifesciences Holdings Inc   61.82 %
Medpace Holdings Inc   60.42 %
Harmony Biosciences Holdings inc   60.10 %
Shockwave Medical Inc   59.99 %
Sensus Healthcare Inc   53.08 %
Molecular Partners Ag  50.11 %
Biontech Se  47.04 %
Moderna Inc   46.34 %
Zoetis Inc   46.13 %
Nrc Health  43.88 %
Tenet Healthcare Corp  43.83 %
Cartesian Therapeutics Inc   43.66 %
Skinhealth Systems Inc   42.57 %
Zymeworks Inc   42.24 %
3m Company  40.11 %

Date modified: 2026-08-29T07:14:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.